These results were largely reproduced in wild-type mice infused with Ang II and concurrently treated with an orally absorbable NHE3 inhibitor, AVE-0657 (20 mg/kg/day for 14–28 days), which also significantly attenuated Ang II-induced hypertension in C57BL/6J mice (Li et al., 2019a). The gene discussed is AGT; the disease is hypertensive disorder.